Expanding access to obesity medications for teenagers could prevent substantial adult health complications, but current treatment gaps significantly undermine potential population benefits. Economic modeling reveals a complex landscape where newer interventions offer meaningful health gains at costs that challenge traditional healthcare budgets.
Analysis of 1000 simulated adolescents tracked from ages 12 to 26 found phentermine-topiramate combinations cost approximately $112,141 per quality-adjusted life year gained compared to standard lifestyle interventions. Semaglutide, the newer GLP-1 receptor agonist, required an additional $166,513 per QALY when compared to the combination therapy. These figures place both treatments in economically contested territory—above many healthcare system willingness-to-pay thresholds yet potentially justified by long-term obesity prevention.
The analysis exposes a troubling reality: imperfect healthcare access reduces cost-effectiveness by 11% while substantially decreasing prevented obesity cases. Insurance coverage disparities and racial barriers to specialty care create a two-tier system where economic benefits concentrate among privileged populations while underserved communities bear disproportionate disease burden.
This research arrives as pediatric obesity rates plateau but remain historically elevated, with emerging pharmacological options creating new treatment paradigms. The cost-effectiveness calculations assume perfect medication adherence and sustained access—optimistic assumptions given real-world treatment discontinuation rates. The modeling also cannot capture potential societal benefits from reduced obesity-related healthcare utilization decades later, suggesting these interventions may prove more economically attractive than current estimates indicate.